Biocompounds Pharmaceutical Inc. (Biocompounds), founded in 2003, is a high-tech enterprise integrating R&D, manufacturing, and sales, focusing on pharmaceutical APIs, intermediates, and agrochemical TC.

The company has been recognized as a national-level "Little Giant" enterprise, and hosts an expert workstation and a small-molecule targeted drug research institute. It is also accredited as a Shanghai High-tech Enterprise, Songjiang District Enterprise Technology Center, and a G60 key support enterprise.

In 2018, Biocompounds Pharmaceutical was controlled by Zhejiang Jianfeng Pharmaceutical Co., Ltd., a subsidiary of the listed company Zhejiang Jianfeng Group (stock code: 600668), and officially became the "intermediate + active pharmaceutical ingredient" production base, a core part of Jianfeng Pharmaceutical's integrated strategy of "intermediate + active pharmaceutical ingredient + formulation".

Relying on the resources and management advantages of listed companies, Biocompounds Pharmaceutical has embarked on a fast track of high-quality development, committed to providing the most competitive raw material solutions for the health industry.

Committed to "green processes and lean manufacturing," Biocompounds aims to become a premier platform for process innovation and lean production, delivering high-quality, cost-competitive APIs, intermediates, and agrochemical TC.

Our core values emphasize customer value creation, people-orientation, continuous improvement, lean management, and teamwork. Guided by technology leadership, lean excellence, quality foundation, and cost efficiency, we drive full-process cost reduction and productivity enhancement.

Strategically, we focus on product management—vertically reducing costs and horizontally replicating success across product lines. Our long-term goal is to develop differentiated and patented APIs and intermediates with superior quality and cost advantages through lean manufacturing.

Biocompounds operates two wholly-owned subsidiaries in the Dongzhi Economic Development Zone, Chizhou, Anhui: Anhui Bocompounds Pharmaceutical Co., Ltd. and Anhui Biocompounds Chemicals Co., Ltd., covering a combined area of 400 mu (≈26.7 hectares). Both are recognized as key emerging industry enterprises in Anhui Province.

Shanghai Biocompounds serves as the R&D and sales hub, driving innovation and customer development, while the Anhui subsidiaries handle product conversion, manufacturing, quality, and cost control, creating an efficient integrated chain from R&D to production.

We continuously invest in technology, safety, and environmental protection, embedding green, safe, and efficient principles from process design. We are advancing GMP-compliant research and production of APIs and advanced intermediates in both Shanghai and Anhui, offering global pharmaceutical partners one-stop support from intermediates to APIs.